CytomX Therapeutics shares are trading lower after the company reported Q4 financial results. Also, BMO Capital maintained a Market Perform rating on the stock and lowered its price target from $3.3 to $3.25.
Portfolio Pulse from Benzinga Newsdesk
CytomX Therapeutics' shares dropped following the announcement of their Q4 financial results. Additionally, BMO Capital has maintained a Market Perform rating on CTMX but reduced its price target from $3.3 to $3.25.
March 12, 2024 | 4:50 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
CytomX Therapeutics' stock price declined following their Q4 earnings report and a slight reduction in price target by BMO Capital.
The decline in CytomX Therapeutics' stock price is directly related to the reported Q4 financial results, which likely did not meet investor expectations. Additionally, the reduction in the price target by BMO Capital, although minor, could contribute to negative sentiment among investors, further impacting the stock price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100